Metabolites,
Journal Year:
2018,
Volume and Issue:
8(1), P. 13 - 13
Published: Feb. 10, 2018
Carbonic
anhydrase
IX
has
been
under
intensive
investigation
as
a
therapeutic
target
in
cancer.
Studies
demonstrate
that
this
enzyme
key
role
pH
regulation
cancer
cells,
allowing
these
cells
to
adapt
the
adverse
conditions
of
tumour
microenviroment.
Novel
CAIX
inhibitors
have
shown
efficacy
both
vitro
and
vivo
pre-clinical
models,
adversely
affecting
cell
viability,
formation,
migration,
invasion,
metastatic
growth
when
used
alone.
In
co-treatments,
may
enhance
effects
anti-angiogenic
drugs
or
chemotherapy
agents.
Research
suggests
also
increase
response
tumours
radiotherapy.
Although
many
anti-tumour
inhibition
be
dependent
on
its
regulation,
recent
work
interacts
with
several
signalling
pathways
involved
cellular
radiation,
suggesting
pH-independent
mechanisms
an
important
basis
progression.
Here,
we
discuss
interactions
context
ability
modulate
responsiveness
radiation.
Cancer and Metastasis Reviews,
Journal Year:
2019,
Volume and Issue:
38(1-2), P. 65 - 77
Published: May 10, 2019
Cancer
development
is
a
complex
process
that
follows
an
intricate
scenario
with
dynamic
interplay
of
selective
and
adaptive
steps
extensive
cast
molecules
signaling
pathways.
Solid
tumor
initially
grows
as
avascular
bulk
cells
carrying
oncogenic
mutations
until
diffusion
distances
from
the
nearest
functional
blood
vessels
limit
delivery
nutrients
oxygen
on
one
hand
removal
metabolic
waste
other
one.
These
restrictions
result
in
regional
hypoxia
acidosis
select
for
adaptable
able
to
promote
aberrant
angiogenesis,
remodel
metabolism,
acquire
invasiveness
metastatic
propensity,
gain
therapeutic
resistance.
Tumor
are
thereby
endowed
capability
survive
proliferate
hostile
microenvironment,
communicate
stroma,
enter
circulation,
colonize
secondary
sites,
generate
metastases.
While
role
initializing
driving
these
processes
well
established,
key
contribution
non-genomic,
landscaping
molecular
players
still
less
appreciated
despite
they
can
equally
serve
viable
targets
anticancer
therapies.
Carbonic
anhydrase
IX
(CA
IX)
players:
it
induced
by
hypoxia,
functionally
linked
acidosis,
implicated
invasiveness,
correlated
Here,
we
summarize
available
experimental
evidence
supported
accumulating
preclinical
clinical
data
CA
contribute
virtually
each
step
cancer
progression
path
via
its
enzyme
activity
and/or
non-catalytic
mechanisms.
We
also
propose
targeting
express
may
provide
benefits
various
settings
combinations
both
conventional
newly
developed
treatments.
Metabolites,
Journal Year:
2018,
Volume and Issue:
8(1), P. 19 - 19
Published: Feb. 28, 2018
The
pH
of
the
tumor
microenvironment
drives
metastatic
phenotype
and
chemotherapeutic
resistance
tumors.
Understanding
mechanisms
underlying
this
pH-dependent
phenomenon
will
lead
to
improved
drug
delivery
allow
identification
new
therapeutic
targets.
This
includes
an
understanding
role
plays
in
primary
cells,
regulatory
factors
that
permit
cancer
cells
thrive.
Over
last
decade,
carbonic
anhydrases
(CAs)
have
been
shown
be
important
mediators
cell
by
modulating
bicarbonate
proton
concentrations
for
survival
proliferation.
has
prompted
effort
inhibit
specific
CA
isoforms,
as
anti-cancer
strategy.
Of
12
active
two,
IX
XII,
considered
However,
other
isoforms
also
show
similar
activity
tissue
distribution
cancers
not
targets
treatment.
In
review,
we
consider
all
their
possible
tumors
potential
therapy.
Medicinal Research Reviews,
Journal Year:
2018,
Volume and Issue:
38(6), P. 1799 - 1836
Published: April 10, 2018
Human
carbonic
anhydrase
(CA)
IX
is
a
tumor-associated
protein,
since
it
scarcely
present
in
normal
tissues,
but
highly
overexpressed
large
number
of
solid
tumors,
where
actively
contributes
to
survival
and
metastatic
spread
tumor
cells.
Due
these
features,
the
characterization
its
biochemical,
structural,
functional
features
for
drug
design
purposes
has
been
extensively
carried
out,
with
consequent
development
several
selective
small
molecule
inhibitors
monoclonal
antibodies
be
used
different
purposes.
Aim
this
review
provide
comprehensive
state-of-the-art
studies
performed
on
enzyme,
regarding
functional,
biomedical
aspects,
as
well
molecules
diagnostic
therapeutic
applications
cancer
treatment.
A
brief
description
additional
pharmacologic
CA
inhibition
other
diseases,
such
arthritis
ischemia,
also
provided.
Metabolites,
Journal Year:
2017,
Volume and Issue:
7(3), P. 48 - 48
Published: Sept. 16, 2017
Hypoxia
and
acidosis
are
salient
features
of
many
tumors,
leading
to
a
completely
different
metabolism
compared
normal
cells.
Two
the
simplest
metabolic
products,
protons
bicarbonate,
generated
by
catalytic
activity
metalloenzyme
carbonic
anhydrase
(CA,
EC
4.2.1.1),
with
at
least
two
its
isoforms,
CA
IX
XII,
mainly
present
in
hypoxic
tumors.
Inhibition
tumor-associated
CAs
leads
an
impaired
growth
primary
metastases
reduces
population
cancer
stem
cells,
thus
complex
beneficial
anticancer
action
for
this
class
enzyme
inhibitors.
In
review,
I
will
state
art
on
development
inhibitors
(CAIs)
targeting
which
may
have
applications
treatment
imaging
cancers
expressing
them.
Small
molecule
inhibitors,
one
(SLC-0111)
completed
Phase
clinical
trials,
antibodies
(girentuximab,
discontinued
III
trials)
be
discussed,
together
various
approaches
used
design
agents
new
mechanism
based
interference
these
crucial
metabolites,
bicarbonate.
Expert Opinion on Investigational Drugs,
Journal Year:
2018,
Volume and Issue:
27(12), P. 963 - 970
Published: Nov. 14, 2018
Introduction:
Hypoxic
tumors
overexpress
two
carbonic
anhydrases
(CA,
EC
4.2.1.1),
CA
IX
and
XII,
involved
in
complex
processes
connected
to
tumorigenesis
(pH
regulation,
metabolism,
invasion,
dissemination
of
the
tumor).
The
biochemical
rationale
behind
these
is
orchestrated
by
transcription
factor
hypoxia
inducible
1
(HIF-1).Areas
covered:
XII
have
been
validated
as
antitumor/antimetastatic
drug
targets
may
be
used
for
imaging
hypoxic
tumors.
Many
inhibitors
(CAIs)
belonging
sulfonamide,
coumarin
sulfocoumarin
classes
selectively
inhibit
isoforms.
IX/XII
growth
primary
formation
metastases
deplete
cancer
stem
cell
population,
alone
or
combination
with
other
agents.
These
are
three
beneficial
antitumor
mechanisms
that
make
them
unique
among
anticancer
drugs
available.Expert
opinion:
Indisulam
entered
clinical
trials
an
sulfonamide;
it
progressed
Phase
II
but
was
terminated
2016.
However,
SLC-0111,
a
sulfonamide
inhibitor
1,
recently
completed
successful
I
trial
treatment
advanced,
metastatic
solid
This
compound
now
Ib/II
being
assessed
monotherapy
agents
such
gemcitabine.
synergistic
(cisplatin,
proton
pump
inhibitors,
doxorubicin,
temozolamide)
versatile,
emerging
class
drugs.
Gastroenterology,
Journal Year:
2019,
Volume and Issue:
157(3), P. 823 - 837
Published: May 9, 2019
Most
pancreatic
ductal
adenocarcinomas
(PDACs)
express
an
activated
form
of
KRAS,
become
hypoxic
and
dysplastic,
are
refractory
to
chemo
radiation
therapies.
To
survive
in
the
environment,
PDAC
cells
upregulate
enzymes
transporters
involved
pH
regulation,
including
extracellular
facing
carbonic
anhydrase
9
(CA9).
We
evaluated
effect
blocking
CA9,
combination
with
administration
gemcitabine,
mouse
models
cancer.We
knocked
down
expression
KRAS
human
(PK-8
PK-1)
small
hairpin
RNAs.
Human
(KrasG12D/Pdx1-Cre/Tp53/RosaYFP)
were
incubated
inhibitors
MEK
(trametinib)
or
signal-regulated
kinase
(ERK),
some
cultured
under
conditions.
measured
levels
stability
hypoxia-inducible
factor
1
subunit
alpha
(HIF1A),
endothelial
PAS
domain
protein
(EPAS1,
also
called
HIF2A),
solute
carrier
family
16
member
4
(SLC16A4,
MCT4),
SLC2A1
(also
GLUT1)
by
immunoblot
analyses.
analyzed
intracellular
(pHi)
metabolic
flux.
CA9
cells,
inhibited
SLC-0111,
them
assessed
pHi,
flux,
cytotoxicity
normoxic
Cells
injected
into
either
immune-compromised
immune-competent
mice
growth
xenograft
tumors
was
assessed.
Tumor
fragments
derived
from
patients
surgically
ligated
pancreas
performed
tissue
microarray
analyses
205
samples
measure
associated
genes
that
regulate
hypoxia
outcomes
using
Cancer
Genome
Atlas
database.Under
conditions,
had
increased
HIF1A
HIF2A,
upregulated
glycolysis.
Knockdown
incubation
trametinib,
reduced
posttranscriptional
stabilization
upregulation
glycolysis
response
hypoxia.
expressed
66%
analyzed;
high
adaptation
hypoxia,
correlated
significantly
survival
times
patients.
pharmacologic
inhibition
pHi
decreased
gemcitabine-induced
glycolysis,
their
sensitivity
gemcitabine.
knockdown
formed
smaller
mice,
injection
gemcitabine
tumor
mice.
In
grown
oral
SLC-0111
intratumor
acidosis
cell
death.
These
tumors,
patient-derived
fragments,
grew
more
slowly
than
given
control
agents,
resulting
longer
times.
KrasG12D/Pdx1-Cre/Tp53/RosaYFP
genetically
modified
numbers
B
tumors.In
increase
via
Disruption
this
pathway
slows
might
be
developed
for
treatment
cancer.
Advanced Functional Materials,
Journal Year:
2019,
Volume and Issue:
30(6)
Published: Nov. 29, 2019
Abstract
Chemodynamic
therapy
(CDT)
by
introducing
the
Fenton‐/Fenton‐like
reaction
in
an
acidic
and
H
2
O
environment
for
toxic
hydroxyl
radical
(•OH)
generation,
is
a
newly
developed
tumor‐selective
therapeutic.
However,
tumor
acidosis,
characterized
extracellular
acidity
(pH
e
≈
6.5)
intracellular
alkalinity
i
7.2),
undoubtedly
confers
large
chemical
barrier
effective
implementation
of
CDT
thus
limits
its
functional
activity
therapeutic
efficacy.
Here,
unique
amorphous
iron
nanoparticles
(AFeNPs)
loaded
with
carbonic
anhydrase
IX
inhibitor
(CAI)
are
constructed
to
re‐establish
acidosis
decreased
pH
increased
via
inhibiting
over‐expressed
CA
cancer
cells
CAI
self‐enhanced
CDT.
The
suppression
leads
+
accumulation
that
could
accelerate
AFeNPs‐based
Fenton
drastically
exacerbate
oxidative
stress
subsequently
induce
cell
death;
meanwhile,
inhibition
formation
outside
efficiently
represses
potential
invasion
metastasis
owing
insufficient
ions
degradation
matrix.
Re‐established
not
only
assists
optimization
CDT,
but
also
presents
opportunity
development
new
antitumor
methods
more
tumor‐acidity
specific.
Metabolites,
Journal Year:
2020,
Volume and Issue:
10(10), P. 412 - 412
Published: Oct. 14, 2020
The
tumor
microenvironment
is
crucial
for
the
growth
of
cancer
cells,
triggering
particular
biochemical
and
physiological
changes,
which
frequently
influence
outcome
anticancer
therapies.
rationale
behind
many
these
phenomena
resides
in
activation
transcription
factors
such
as
hypoxia-inducible
factor
1
2
(HIF-1/2).
In
turn,
HIF
pathway
activates
a
number
genes
including
those
involved
glucose
metabolism,
angiogenesis,
pH
regulation.
Several
carbonic
anhydrase
(CA,
EC
4.2.1.1)
isoforms,
CA
IX
XII,
actively
participate
processes
were
validated
antitumor/antimetastatic
drug
targets.
Here,
we
review
field
inhibitors
(CAIs),
selectively
inhibit
cancer-associated
isoforms.
Particular
focus
was
on
identification
lead
compounds
various
inhibitor
classes,
measurement
inhibitory
on-/off-target
effects.
addition,
preclinical
data
that
resulted
SLC-0111,
sulfonamide
Phase
Ib/II
clinical
trials
treatment
hypoxic,
advanced
solid
tumors,
are
detailed.
Physiological Reviews,
Journal Year:
2022,
Volume and Issue:
102(3), P. 1327 - 1383
Published: Feb. 15, 2022
During
the
past
three
decades,
mice,
zebrafish,
fruit
flies,
and
Caenorhabditis
elegans
have
been
primary
model
organisms
used
for
study
of
various
biological
phenomena.
These
models
also
adopted
developed
to
investigate
physiological
roles
carbonic
anhydrases
(CAs)
anhydrase-related
proteins
(CARPs).
belong
eight
CA
families
are
identified
by
Greek
letters:
α,
β,
γ,
δ,
ζ,
η,
θ,
ι.
Studies
using
focused
on
two
families,
α-CAs
β-CAs,
which
expressed
in
both
prokaryotic
eukaryotic
with
species-specific
distribution
patterns
unique
functions.
This
review
covers
CAs
CARPs
light
investigations
performed
organisms.
Functional
studies
demonstrate
that
not
only
linked
regulation
pH
homeostasis,
classical
role
CAs,
but
contribute
a
plethora
previously
undescribed